NEWLINK GENETICS CORPORATION

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Non-small Cell Lung Cancer Recurrent
Non-small Cell Lung Cancer
Progression of Non-small Cell Lung Cancer

Interventions: Drug: Docetaxel
Biological: HyperAcute®-Lung Immunotherapy
Drug: Gemcitabine
Drug: Pemetrexed

First Posted Date: 2013-01-24

Last Posted Date: 2020-05-28

Lead Sponsor: NewLink Genetics Corporation

Target Recruit Count: 135

Registration Number: NCT01774578

Locations: 🇺🇸
St. Joseph Heritage Healthcare, Santa Rosa, California, United States
🇺🇸
Illinois Cancer Specialists, Arlington Heights, Illinois, United States
🇺🇸
Deaconess Clinic, Evansville, Indiana, United States

and more 21 locations

A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: CRLX101
Other: Best Supportive Care

First Posted Date: 2011-06-27

Last Posted Date: 2020-05-28

Lead Sponsor: NewLink Genetics Corporation

Target Recruit Count: 157

Registration Number: NCT01380769

Locations: 🇷🇺
State Healthcare Institution: Bryansk Regional Oncology Center, Bryansk, Russian Federation
🇷🇺
Kursk Regional Oncology Center, Kursk, Russian Federation
🇷🇺
Non-Government Medical Institution: Central Clinical Hospital #2, Moscow, Russian Federation

and more 22 locations

Immunotherapy Study for Surgically Resected Pancreatic Cancer

Phase 3

Completed

Conditions: Pancreatic Cancer

Interventions: Biological: HyperAcute-Pancreas Immunotherapy
Radiation: 5FU Chemoradiation
Drug: Gemcitabine

First Posted Date: 2010-02-22

Last Posted Date: 2020-05-28

Lead Sponsor: NewLink Genetics Corporation

Target Recruit Count: 722

Registration Number: NCT01072981

Locations: 🇺🇸
Stamford Hospital, Stamford, Connecticut, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 71 locations

Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.

Phase 2

Withdrawn

Conditions: Ovarian Cancer
Solid Tumor
Cancer

Interventions: Drug: IT-101 (15mg/m2/dose)
Drug: IT-101 (12mg/m2/dose)
Drug: 5% Dextrose (Placebo)

First Posted Date: 2008-09-16

Last Posted Date: 2020-06-12

Lead Sponsor: NewLink Genetics Corporation

Registration Number: NCT00753740

Locations: 🇺🇸
Schwartz Gynecologic Onclology, PLLC, Brightwaters, New York, United States
🇺🇸
Riverside Gynecology & Oncology, Newport News, Virginia, United States
🇺🇸
Decatur Memorial Hospital, Clinical Research Department/ Cancer Care Specialists of Illinois, Decatur, Illinois, United States

and more 4 locations

IDO Inhibitor Study for Relapsed or Refractory Solid Tumors

Phase 1

Terminated

Conditions: Pancreatic Cancer
Breast Cancer
Lung Cancer
Melanoma
Solid Tumors

Interventions: Drug: 1-methyl-D-tryptophan

First Posted Date: 2008-08-22

Last Posted Date: 2020-05-28

Lead Sponsor: NewLink Genetics Corporation

Target Recruit Count: 17

Registration Number: NCT00739609

Locations: 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States

Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer

Phase 2

Terminated

Conditions: Pancreatic Cancer

Interventions: Biological: HyperAcute(R)-Pancreatic Cancer Vaccine

First Posted Date: 2008-02-13

Last Posted Date: 2020-05-28

Lead Sponsor: NewLink Genetics Corporation

Target Recruit Count: 9

Registration Number: NCT00614601

Locations: 🇺🇸
University of Louisville, Louisville, Kentucky, United States

Vaccine Study for Surgically Resected Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Biological: HyperAcute(R)-Pancreatic Cancer Vaccine

First Posted Date: 2007-12-07

Last Posted Date: 2020-05-28

Lead Sponsor: NewLink Genetics Corporation

Target Recruit Count: 73

Registration Number: NCT00569387

Locations: 🇺🇸
Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Evanston Northwestern Healthcare, Evanston, Illinois, United States

and more 15 locations

Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Biological: HyperAcute-Lung Cancer Vaccine

First Posted Date: 2007-01-11

Last Posted Date: 2020-05-28

Lead Sponsor: NewLink Genetics Corporation

Target Recruit Count: 6

Registration Number: NCT00420732

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Washington University in St. Louis, Saint Louis, Missouri, United States

Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor
Cancer

Interventions: Drug: Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer

First Posted Date: 2006-06-05

Last Posted Date: 2020-05-28

Lead Sponsor: NewLink Genetics Corporation

Target Recruit Count: 62

Registration Number: NCT00333502

Locations: 🇺🇸
Virginia G. Piper Cancer Center, Scottsdale, Arizona, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
San Juan Oncology Associates, Farmington, New Mexico, United States

Vaccine Treatment for Advanced Malignant Melanoma

Phase 1

Completed

Conditions: Malignant Melanoma

Interventions: Biological: HyperAcute-Melanoma Vaccine

First Posted Date: 2006-03-09

Last Posted Date: 2020-05-28

Lead Sponsor: NewLink Genetics Corporation

Target Recruit Count: 6

Registration Number: NCT00300612

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy